未登录

E

Euphemia Leung

Auckland Cancer Society

H指数:40

被引数:5,727

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BIRC5 Promoter-Driven Nanodrugs Suppress BIRC5-Positive Cancers Independent of ABCB1 Status and IDO1 Expression

BIRC5启动子驱动的纳米药物抑制BIRC5阳性癌症，与ABCB1状态和IDO1表达无关

International Journal of Nanomedicine

IF6.5

2026-04-280

OAAI

Common Variable Immunodeficiency Disorders: A perspective from New Zealand

常见变异型免疫缺陷病：来自新西兰的视角

Clinical Reviews in Allergy & Immunology

IF11.3

2025-12-010

OAAI

Opinion: the evolving understanding of polygenic common variable immunodeficiency-like disorders

观点：对多基因常见变异免疫缺陷样疾病的不断发展的理解

Frontiers in Immunology

IF5.9

2025-08-280

OA

Synthesis and investigation of thieno[2; 3-b]pyridines that restore activity of topotecan

噻吩并[2; 3-b]吡啶的合成及其恢复拓扑替康活性的研究

IF3.6

2025-08-220

PRE

Design, synthesis, and SAR of antiproliferative activity of trioxatriangulene derivatives

RSC MEDICINAL CHEMISTRY

IF3.6

2025-03-010

PRE

N-formylkynurenine but not kynurenine enters a nucleophile-scavenging branch of the immune-regulatory kynurenine pathway

N-甲酰基犬尿氨酸但不是犬尿氨酸进入免疫调节犬尿氨酸通路中的亲核试剂清除分支。

BIOORGANIC CHEMISTRY

IF4.7

2025-03-010

OAAI

NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen breast cancer cells

JOURNAL OF CANCER

IF3.2

2025-02-110

OAAI

Structure-activity relationship expansion and microsomal stability assessment of the 2-morpholinobenzoic acid scaffold as antiproliferative phosphatidylcholine-specific phospholipase C inhibitors

RSC MEDICINAL CHEMISTRY

IF3.6

2025-01-010

PRE

Characterizing Extracellular Vesicles Generated from the Integra CELLine Culture System and Their Endocytic Pathways for Intracellular Drug Delivery

IF5.5

2024-09-130

OAAI

Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells

JOURNAL OF LIPOSOME RESEARCH

IF4.3

2024-01-255

OA

Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IF3.8

2023-08-113

PRE

Phosphatidylcholine-Specific Phospholipase C as a Promising Drug Target

IF4.6

2023-07-255

OAAI

Functionalisation of extracellular vesicles with cyclic-RGDyC potentially for glioblastoma targeted intracellular drug delivery

BIOMATERIALS ADVANCES

IF6

2023-06-0114

PRE

The Rapidly Expanding Genetic Spectrum of Common Variable ImmunodeficiencyeLike Disorders

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

IF6.6

2023-06-0115

PRE

Investigation of 2-phenylimidazo[1,2-a]quinolines as potential antiproliferative agents

FUTURE MEDICINAL CHEMISTRY

IF3.4

2023-03-090

PRE

Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

IF6.6

2023-01-017

OAAI

Impact of Coordination Mode and Ferrocene Functionalization on the Anticancer Activity of N-Heterocyclic Carbene Half-Sandwich Complexes

配位方式和二茂铁功能化对N-杂环卡宾半夹心配合物抗癌活性的影响

INORGANIC CHEMISTRY

IF4.7

2022-10-149

PRE

A simple approach to re-engineering small extracellular vesicles to circumvent endosome entrapment

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2022-10-0111

PRE

SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

IF6.6

2022-09-0110

OAAI

Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2

EXPERT REVIEW OF CLINICAL IMMUNOLOGY

IF3.7

2022-05-2611

PRE